Curated News
By: NewsRamp Editorial Staff
April 29, 2024
IceCure's ProSense® Cryoablation Therapy Shows Promising Results for Early-Stage Breast Cancer
TLDR
- IceCure Medical Ltd. is one step closer to getting FDA approval for ProSense®, a cryoablation therapy with 100% patient and physician satisfaction.
- ProSense® is a liquid-nitrogen-based cryoablation therapy that destroys tumors, with 96.3% of patients estimated to be free from local recurrence at the 5-year follow-up evaluation.
- ProSense® provides a minimally invasive, effective, and cost-saving treatment option for women with early-stage T1 invasive breast cancer, potentially improving patient care.
- Cryoablation with ProSense® is a breakthrough, minimally invasive treatment with potential to become a new standard of care for breast cancer, offering a less invasive alternative to surgery.
Impact - Why it Matters
IceCure's ProSense® cryoablation therapy offers a minimally invasive, effective, and potentially more cost-efficient alternative to traditional lumpectomy surgery for early-stage breast cancer patients. The therapy's high patient and physician satisfaction, along with its 96.3% recurrence-free rate, could significantly improve the treatment options and outcomes for women diagnosed with invasive breast cancer.
Summary
IceCure Medical Ltd. (NASDAQ: ICCM) has reported final clinical trial results of 100% patient and physician satisfaction with ProSense® cryoablation therapy for early-stage T1 invasive breast cancer. The company submitted its final data to the FDA, including five-year follow-up data from the ICE3 study, showing a 96.3% recurrence-free rate. The therapy is one step closer to FDA approval for treating early-stage breast cancer, with the potential to become a new standard of care treatment.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, IceCure's ProSense® Cryoablation Therapy Shows Promising Results for Early-Stage Breast Cancer
